TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33814028

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 1183

Group type: COMPARATOR
Intervention: MenACYW-TT + MMR + V
Number of subjects: 1183

Group type: COMPARATOR
Intervention: MenACYW-TT + DTaP-IPV-HepB-Hib
Number of subjects: 1183

Group type: COMPARATOR
Intervention: MenACYW-TT + PCV13
Number of subjects: 1183

Group type: COMPARATOR
Intervention: MMR + V, DTaP-IPV-HepB-Hib, and PCV13
Number of subjects: 1183
Study: 35997810

Group type: EXPERIMENTAL
Intervention: EX‐PLISSIT‐based counseling sessions for 4 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110
Study: 34611701

Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 440

Group type: COMPARATOR
Intervention: Conventional imaging (Control)
Number of subjects: 440
Study: 32873251

Group type: EXPERIMENTAL
Intervention: 5Gy x 5 fractions of short-course radiation therapy (SCRT) followed by 6 cycles of mFOLFOX-6 plus avelumab
Number of subjects: 44
Study: 34742317

Group type: EXPERIMENTAL
Intervention: Combined exercise (60 min of aerobic and resistance exercise three times/week for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 30
Study: 32589286

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 5604984

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 5604984

Group type: EXPERIMENTAL
Intervention: Plasma transfusion
Number of subjects: 5604984

Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 5604984
Study: 34518988

Group type: EXPERIMENTAL
Intervention: Tislelizumab (monoclonal antibody)
Number of subjects: 248
Study: 32993766

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) in addition to standard treatment (dressings, debridement, antibiotics, load relief)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment (dressings, debridement, antibiotics, load relief)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups will complete the SF-36 quality of life questionnaire upon admission and after 3 months of follow-up.
Number of subjects: 120
Study: 35331180

Group type: EXPERIMENTAL
Intervention: Abdominal-transhiatal (TH) approach
Number of subjects: 312

Group type: COMPARATOR
Intervention: Right thoracoabdominal (RTA) approach
Number of subjects: 312
Study: 33198700

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (self-help materials only)
Number of subjects: 144
Study: 36480101

Group type: EXPERIMENTAL
Intervention: 4–7–8 breathing technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Deep breathing exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 90
Study: 34757573

Group type: EXPERIMENTAL
Intervention: Training of frontline workers (FLWs) using a training module developed in regional language.
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Control group (no training provided to FLWs).
Number of subjects: 1717
Study: 33179247

Group type: COMPARATOR
Intervention: Rufinamide (add-on treatment)
Number of subjects: 1759
Study: 35015365

Group type: EXPERIMENTAL
Intervention: Self-Help Plus (combined with Enhanced Care as Usual)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Enhanced Care as Usual (ECAU)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Self-Help Plus
Number of subjects: 642
Study: 34231473

Group type: EXPERIMENTAL
Intervention: 1 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 2)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 0.5 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 3)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Clear liquid diet and fasting-based bowel preparation (group 1)
Number of subjects: 166
Study: 32304596

Group type: EXPERIMENTAL
Intervention: Resistance Index (RI) in anterior cerebral artery (ACA)
Number of subjects: 108
Study: 36041790

Group type: EXPERIMENTAL
Intervention: HIF-prolyl-hydroxyl domain (PHD) inhibitors (roxadustat, vadadustat, daprodustat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33957393

Group type: EXPERIMENTAL
Intervention: Intensive management system with broiler and layers in Dodoma Municipal
Number of subjects: 400

Group type: COMPARATOR
Intervention: Free-range management system with local breed chickens in Kongwa district
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Challenges in chicken production
Number of subjects: 400
Study: 32067595

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (compression ball)
Number of subjects: 0
Study: 33274388

Group type: EXPERIMENTAL
Intervention: Early headgear activator treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control group (UG)
Number of subjects: 60
Study: 32931641

Group type: EXPERIMENTAL
Intervention: Distal Roux‐en‐Y gastrojejunal bypass (DRYGJB)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups (RYGB and DRYGJB)
Number of subjects: 140
Study: 36168659

Group type: EXPERIMENTAL
Intervention: Masupirdine 50 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Masupirdine 100 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 33138630

Group type: EXPERIMENTAL
Intervention: Less social support at 9 months
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Going without basic needs or healthcare at 9 months
Number of subjects: 1154
Study: 32436830

Group type: COMPARATOR
Intervention: Intravenous reperfusion therapy (IVT)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Intravenous alteplase combined with mechanical thrombectomy (IAT)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: No cerebral reperfusion therapy (NCRT)
Number of subjects: 917
Study: 35614019

Group type: COMPARATOR
Intervention: Video-based group (group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Simulation-based group (group 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination group (group 3)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3rd-year residents in group 3
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 4th-year residents in group 3
Number of subjects: 33
Study: 34744750

Group type: EXPERIMENTAL
Intervention: SHR-1222 (50 mg, n = 4; 100, 200, 300, or 400 mg, n = 9)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (10 subjects)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SHR-1222
Number of subjects: 50
Study: 35713444

Group type: EXPERIMENTAL
Intervention: Binaural beat music
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Plain music
Number of subjects: 112

Group type: COMPARATOR
Intervention: No music
Number of subjects: 112
Study: 32619223

Group type: EXPERIMENTAL
Intervention: ZnP (1.0 g/[hd · d] additional Zn)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CON (0.0 g/[hd · d] of additional Zn)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 32
Study: 35861826

Group type: EXPERIMENTAL
Intervention: Dialysis vintage ≤12 months
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Dialysis vintage >12 months
Number of subjects: 241
Study: 34940066

Group type: EXPERIMENTAL
Intervention: 3-monthly cardiac monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: 4-monthly cardiac monitoring
Number of subjects: 200
Study: 32239460

Group type: EXPERIMENTAL
Intervention: Individually tailored counselling (one face-to-face session, four phone calls, and supportive written material)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Individually tailored counselling
Number of subjects: 204

Group type: COMPARATOR
Intervention: Written health information (control group)
Number of subjects: 204
Study: 33500169

Group type: EXPERIMENTAL
Intervention: Aromatherapy (lavender essential oil)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 172
Study: 34378247

Group type: EXPERIMENTAL
Intervention: Naftopidil (75 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Silodosin (8 mg/day)
Number of subjects: 141
Study: 35051971

Group type: EXPERIMENTAL
Intervention: Specialized outpatient physical therapy (PT) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: General outpatient PT referral (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Specialized outpatient PT program
Number of subjects: 60
Study: 34448282

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Probiotics supplemented quadruple therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Probiotics monotherapy
Number of subjects: 151
Study: 32398065

Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship programme implemented in intervention arm, including training for family physicians, improved management and peer-review of antibiotic prescribing, improved electronic medical records and smartphone app facilitation, patient education via family physicians, leaflets, and videos.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care in control arm (no specific intervention details provided).
Number of subjects: 34
Study: 35233617

Group type: EXPERIMENTAL
Intervention: SoC + remdesivir
Number of subjects: 665

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 665
Study: 35796224

Group type: COMPARATOR
Intervention: Topical minoxidil 5% gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical methotrexate 1% gel
Number of subjects: 50
Study: 32755632

Group type: EXPERIMENTAL
Intervention: AIM HI training for therapists
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study: 32135136

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: High-risk participants
Number of subjects: 216

Group type: COMPARATOR
Intervention: Low-risk participants
Number of subjects: 216
Study: 35750241

Group type: EXPERIMENTAL
Intervention: Experimental video (empowerment and participatory discourse)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control video (disease and impairment discourse)
Number of subjects: 589
Study: 35212635

Group type: EXPERIMENTAL
Intervention: Stratified blended physiotherapy (e-Exercise LBP)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Face-to-face physiotherapy
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Stratified blended physiotherapy (e-Exercise LBP) in high-risk patients
Number of subjects: 208
Study: 32064843

Group type: EXPERIMENTAL
Intervention: Calcium sulphate (CaS) used in layers to fill the socket after extraction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with gauze and tranexamic acid placed in the extraction site
Number of subjects: 20
Study: 35370712

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BYHW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 34474706

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergy immunotherapy for short ragweed, timothy grass, Dermatophagoides pteronyssinus, and cat and dog dander.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunotherapy (approved tablets).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U.S. liquid extracts for ragweed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General analysis of dosing practices by U.S. allergists.
Number of subjects: 0
Study: 34114978

Group type: EXPERIMENTAL
Intervention: aprepitant in cART naïve individuals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: aprepitant in cART treated individuals
Number of subjects: 57

Group type: COMPARATOR
Intervention: placebo in cART naïve individuals
Number of subjects: 57
Study: 36083850

Group type: EXPERIMENTAL
Intervention: Percutaneous Transforaminal Endoscopic Discectomy (PTED)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Microendoscopic Discectomy (MED)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 241

Group type: COMPARATOR
Intervention: MED
Number of subjects: 241
Study: 32086350

Group type: EXPERIMENTAL
Intervention: 10-session attentional modification group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18-session attentional modification group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-session placebo training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 18-session placebo training group
Number of subjects: 0
Study: 35067976

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 178
Study: 34178863

Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris (CV) 900 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 sessions/week
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CV + HIIT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 35012610

Group type: EXPERIMENTAL
Intervention: CD24Fc
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32036492

Group type: COMPARATOR
Intervention: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/l-leucovorin plus paclitaxel (FLTAX)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/l-leucovin plus paclitaxel (FLTAX)
Number of subjects: 101
Study: 36079720

Group type: EXPERIMENTAL
Intervention: Post-lockdown dietary habits and lifestyle changes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Participants with improved liver status
Number of subjects: 59
Study: 32500276

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of brain diffusion-weighted imaging (DWI) using a scoring template.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quantitative assessment of brain diffusion-weighted imaging (DWI).
Number of subjects: 75
Study: 32667240

Group type: EXPERIMENTAL
Intervention: Collective Narrative Therapy Groups (CNTG)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 89
Study: 33413608

Group type: EXPERIMENTAL
Intervention: Disease-affected meridians (DAM) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-affected meridians (NAM) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham acupuncture (SA) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 32538796

Group type: EXPERIMENTAL
Intervention: VIP-HANA app
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention control app
Number of subjects: 39
Study: 34954935

Group type: EXPERIMENTAL
Intervention: Bundle nursing of citric acid extracorporeal anticoagulation
Number of subjects: 94
Study: 35085502

Group type: EXPERIMENTAL
Intervention: Intravitreal faricimab 6.0 mg up to every 16 weeks
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks
Number of subjects: 1329
Study: 33662176

Group type: EXPERIMENTAL
Intervention: Bi-monthly household visits
Number of subjects: 384
Study: 32093766

Group type: EXPERIMENTAL
Intervention: Nitrosigine (1.5g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (8g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dextrose placebo (8g)
Number of subjects: 24
Study: 36269401

Group type: EXPERIMENTAL
Intervention: Surgical face mask
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: FFP2/K95 mask
Number of subjects: 84

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 84
Study: 32865027

Group type: EXPERIMENTAL
Intervention: Telehealth visits (weekly to biweekly)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Telephone calls (monthly)
Number of subjects: 29
Study: 32631710

Group type: EXPERIMENTAL
Intervention: Sienna XP (1 mL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Sienna XP (1.5 mL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Sienna XP (2 mL)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Radiotracer (Tc-99 m)
Number of subjects: 135
Study: 35279628

Group type: EXPERIMENTAL
Intervention: AT+Vit D
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vit D
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 36207990

Group type: EXPERIMENTAL
Intervention: Rosacea patients with metabolic syndrome
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rosacea patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 79
Study: 35913759

Group type: EXPERIMENTAL
Intervention: ultrasound renal denervation (uRDN)
Number of subjects: 74

Group type: COMPARATOR
Intervention: sham
Number of subjects: 74
Study: 32911242

Group type: EXPERIMENTAL
Intervention: Multi-component pre-operative preparation program (including informative booklet, preoperative tour, educational DVD, therapeutic play intervention)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Informative booklet as routine information preparation
Number of subjects: 241
Study: 35190375

Group type: EXPERIMENTAL
Intervention: ABCP (atezolizumab + bevacizumab + carboplatin/paclitaxel)
Number of subjects: 920

Group type: COMPARATOR
Intervention: BCP (bevacizumab + carboplatin/paclitaxel)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: ACP (atezolizumab + carboplatin/paclitaxel)
Number of subjects: 920
Study: 32600866

Group type: EXPERIMENTAL
Intervention: white ProRoot® MTA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SavDen® MTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (after internal bleaching)
Number of subjects: 30
Study: 34776128

Group type: EXPERIMENTAL
Intervention: Myofascial Release (MR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 32073330

Group type: EXPERIMENTAL
Intervention: TMD pain in adolescence
Number of subjects: 2209

Group type: COMPARATOR
Intervention: No previous history of TMD pain
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: Persistent TMD pain
Number of subjects: 2209
Study: 32898357

Group type: EXPERIMENTAL
Intervention: Group 1: 120 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 118.2 ± 10.0 HU.
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Group 2: 90 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 141.0 ± 18.2 HU.
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Group 3: 100 kV tube voltage, CM dose 0.417 g I/kg; O: Mean attenuation 117.6 ± 13.9 HU.
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Group 4: 90 kV tube voltage, CM dose 0.365 g I/kg; O: Mean attenuation 117.3 ± 21.6 HU.
Number of subjects: 256
Study: 33399241

Group type: EXPERIMENTAL
Intervention: Palbociclib added to endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 0
Study: 33262194

Group type: EXPERIMENTAL
Intervention: Tailored individual health trainer face-to-face and/or telephone support to reduce smoking and increase physical activity (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief written/electronic advice to reduce or quit smoking (control)
Number of subjects: 0
Study: 35134548

Group type: EXPERIMENTAL
Intervention: ECGI-guided driver ablation after pulmonary vein isolation (PVI)
Number of subjects: 40
Study: 34527924

Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy (20 min, one session per day, for two weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Fluidotherapy (same duration and frequency as paraffin bath therapy)
Number of subjects: 77
Study: 32959458

Group type: EXPERIMENTAL
Intervention: CGRP (calcitonin gene-related peptide) intravenous infusion at 1.5μg/min over 20 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) intravenous infusion over 20 minutes
Number of subjects: 30
Study: 35899020

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine with 5 μg dexmedetomidine (group BD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine with 10 mg meperidine (group BM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10 mg bupivacaine (group B)
Number of subjects: 90
Study: 33183558

Group type: EXPERIMENTAL
Intervention: Inorganic NO3- tablets (314 mM NO3-)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (NO3- free tablets)
Number of subjects: 67
Study: 35926074

Group type: EXPERIMENTAL
Intervention: Curated social web application (interactive website) for COVID-19 vaccine confidence
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: LTCW poll (n=8)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: User experience testing (formal n=3, informal)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Community building with 3 LTCW 'community ambassadors'
Number of subjects: 592
Study: 33534044

Group type: EXPERIMENTAL
Intervention: 4Q‐TAP block analgesia
Number of subjects: 68

Group type: COMPARATOR
Intervention: TEA
Number of subjects: 68
Study: 32382924

Group type: EXPERIMENTAL
Intervention: Comfort‐in™ injection system (CIS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical anesthesia (TA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient preference for CIS
Number of subjects: 60
Study: 35909329

Group type: EXPERIMENTAL
Intervention: EV 2 mg + DNG 2-3 mg (n=20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EE 0.03 mg + DNG 2 mg (n=20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: DNG 2 mg (n=19)
Number of subjects: 59
Study: 34548369

Group type: EXPERIMENTAL
Intervention: HED-Start intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study: 32142501

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg once daily for 6 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg once daily for 6 months
Number of subjects: 134